Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821964 · ClinicalTrials.gov registry record · Phase 2
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00821964 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 15 participants.
The verdict
NCT00821964, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG Abraxane
- GENETIC RNA analysis
- DRUG imiquimod
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821964
The ClinicalTrials.gov registry entry for NCT00821964 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00821964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821964 about?
NCT00821964 is a clinical study titled "Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer". This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune sy...
What is the current status of trial NCT00821964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2012-11-29.
What interventions are being tested in trial NCT00821964?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Abraxane (DRUG), RNA analysis (GENETIC), imiquimod (DRUG), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00821964?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.